- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00406848
A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Arcachon, France, 33120
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Douai, France, 59500
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Limoges, France, 87025
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Metz, France, 57020
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nice, France, 06002
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Strasbourg, France, 67000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Valence, France, 26000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Mexico City, Mexico, 14050
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Monterrey, Mexico, 64710
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Ponce, Puerto Rico, 00731-7779
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
California
-
Pasadena, California, United States, 91107
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Sherman Oaks, California, United States, 91403
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Florida
-
Coral Springs, Florida, United States, 33065
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
West Palm Beach, Florida, United States, 33407
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Illinois
-
Hoffman Estates, Illinois, United States, 60194
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70601
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Maryland
-
Gaithersburg, Maryland, United States, 20877
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Glen Burnie, Maryland, United States, 21061
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Massachusetts
-
Fall River, Massachusetts, United States, 02721
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New Hampshire
-
Nashua, New Hampshire, United States, 03060
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New Jersey
-
Toms River, New Jersey, United States, 08755
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New York
-
Olean, New York, United States, 14760
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Staten Island, New York, United States, 10312
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73109
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19139
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Rhode Island
-
Lincoln, Rhode Island, United States, 02865
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Bartlett, Tennessee, United States, 38134
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Memphis, Tennessee, United States, 38105
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
Wichita Falls, Texas, United States, 76309
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
West Virginia
-
Charleston, West Virginia, United States, 25301
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Wisconsin
-
Brown Deer, Wisconsin, United States, 53223
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are male or female outpatients at least 65 years of age who meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder (MDD)
- Have a Mini Mental Score Exam (MMSE) score of at least 20 at Visit 1
- Have a degree of understanding such that the patient can communicate intelligibly with the investigator and study coordinator
Exclusion Criteria:
- Patients judged clinically to be at serious suicidal risk in the opinion of the investigator
- Have any prior history of bipolar disorder, panic disorder, psychosis, schizophrenia, or obsessive-compulsive disorder
- Have any current (within the past 12 months) DSM-IV-TR primary Axis I diagnosis other than MDD
- Have moderate to severe dementia
- Have a serious medical illness, including any cardiovascular (CV), hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require hospitalization within 6 months, in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo for 13 weeks (The first week was placebo lead-in).
This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
|
Experimental: Duloxetine
|
Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks.
This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to 13 Weeks in Hamilton Depression Rating Scale (HAMD-17) Maier Subscale
Time Frame: baseline (Week 1), Week 13
|
The Maier subscale (Items 1,2,7,8,9,10) represents symptoms of depression.
Total subscale scores range from 0 (normal) to 24 (severe).
|
baseline (Week 1), Week 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline on the 30-item Geriatric Depression Scale (GDS)
Time Frame: baseline (Week 1), Week 13, Week 25
|
The 30-item Geriatric Depression Scale (GDS) is a self-administered test of 30 questions to measure the severity of depression.
The yes/no questions result in a range of scores from 0 (normal) to 30 (severe depression).
|
baseline (Week 1), Week 13, Week 25
|
Change From Baseline in the HAMD-17 Total Score, Subscales, and Individual Items
Time Frame: baseline (Week 1), Week 13, Week 25
|
Total Score assess depression severity (scores 0-52).
Core, Maier and Bech subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier; 0-22=Bech).
Anxiety/Somatization subscale assesses severity of anxiety (0-18).
Retardation subscale assesses dysfunction in mood and work (0-14).
Sleep subscale assesses insomnia (0-6).
Individual item scores may range from 0-4 or 0-2.
Higher numbers indicate more severe symptoms.
|
baseline (Week 1), Week 13, Week 25
|
Change From Baseline in the Brief Pain Inventory (BPI) Severity and Interference Scores
Time Frame: baseline (Week 1), Week 13, Week 25
|
The Brief Pain Inventory (severity and interference scales) (BPI) is a self-reported scale that measures the severity of pain and the interference of pain on function.
Severity scores: 0 (no pain) to 10 (severe pain) on each question assessing worst pain, least pain, and average pain in past 24 hours, and pain right now.
Interference scores: 0 (does not interfere) to 10 (completely interferes) on each question assessing interference of pain in past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.
|
baseline (Week 1), Week 13, Week 25
|
Change From Baseline in the Numeric Rating Scales (NRS) for Pain Item Scores
Time Frame: baseline (Week 1), Week 13, Week 25
|
Numeric Rating Scales (Semantic Differential Scales) for Pain are 6 self-administered scales that assesses experience of overall pain, back pain, headache, shoulder pain, time in pain while awake, and pain interference with daily activities, during the past week.
Each item is scored on a numeric 11-point semantic differential scale (0-10) from 0 = no pain to 10 = pain as severe as you can imagine; or 0 = none of the time to 10 = all of the time; or 0 = no interference to 10 = unable to do any activities at all.
|
baseline (Week 1), Week 13, Week 25
|
Patient's Global Impression of Improvement (PGI-I) at 13 Weeks and 25 Weeks
Time Frame: Week 13, Week 25
|
The PGI-Improvement scale is a patient-rated instrument that measures perceived improvement in symptoms.
It is a 7-point scale where a score of 1 indicates that the patient is "very much improved," a score of 4 indicates that the patient has experienced "no change," and a score of 7 indicates that the patient is "very much worse."
|
Week 13, Week 25
|
Change From Baseline in the Clinical Global Impression-Severity (CGI-S)
Time Frame: baseline (Week 1), Week 13, Week 25
|
Measures severity of illness at the time of assessment.
Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
|
baseline (Week 1), Week 13, Week 25
|
Change From Baseline in the Mini-Mental State Exam (MMSE)
Time Frame: baseline (Week 1), Week 9, Week 25
|
Mini-Mental State Examination (MMSE)is a widely used rating measure of cognitive ability.
Scores range from 0 to 30.
The MMSE will be used to categorize patients as with or without dementia.
Higher number indicates better cognitive ability.
Patients with a MMSE score of 20 to 23 will be categorized as having mild dementia, while those with a score of ≥ 24 will be categorized as having no dementia.
|
baseline (Week 1), Week 9, Week 25
|
Change From Baseline in the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q-SF)
Time Frame: baseline (Week 1), Week 13, Week 25
|
The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) measures the degree of enjoyment and satisfaction experienced in various areas of daily life.
The short version is a self-administered 16 item scale evaluating satisfaction of general activities on a 5-point Likert scale that indicates the degree of enjoyment or satisfaction achieved during the past week (1 = very poor and 5 = very good).
|
baseline (Week 1), Week 13, Week 25
|
Probability of Remission as Measured by the HAMD-17 Total Score ≤7 and ≤10
Time Frame: Week 13, Week 25
|
Remission (visitwise binary outcome, yes/no) is defined as HAMD-17 Total Score ≤7 and ≤10.
HAMD-17 measures depression severity.
The total score can range from 0 (normal) to 52 (severe depression).
The visitwise probability of patients meeting criteria for remission (either Total Score ≤7 or ≤10) was analyzed using a categorical, pseudo-likelihood-based repeated measures approach.
This analysis included the fixed, categorical effects of treatment, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score.
|
Week 13, Week 25
|
Probability of Response at Endpoint as Measured by ≥50% Improvement in the HAMD-17 Total Score
Time Frame: Week 13, Week 25
|
Response (visitwise binary outcome, yes/no) is defined as ≥ 50% reduction from baseline in the HAMD-17 total score.
HAMD-17 measures depression severity.
The total score can range from 0 (normal) to 52 (severe depression).
The visitwise probability of patients meeting criteria for response was analyzed using a categorical, pseudo-likelihood-based repeated measures approach.
This analysis included the fixed, categorical effects of treatment, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score.
|
Week 13, Week 25
|
Probability of Remission as Measured by the HAMD-17 Total Score ≤7 and ≤10 by Medical Comorbidity Severity as Assessed by the Cumulative Illness Rating Scale-Geriatric Version (CIRS-G)
Time Frame: Week 13, Week 25
|
Remission defined as HAMD-17 Total Score ≤7 and ≤10.
HAMD-17 measures depression severity.
Total score ranges: 0 (normal) to 52 (severe depression).
Visitwise probability of patients achieving remission was analyzed using a categorical, pseudo-likelihood-based repeated measures approach.
CIRS-G evaluates 14 organ-specific categories using a rating strategy of 0=no problems; 1=current mild problem/past significant problem; 2=moderate disability/morbidity; 3=severe/constant significant disability; and 4=extremely severe/immediate treatment required/end organ failure.
Total score ranges: 0 to 56.
|
Week 13, Week 25
|
Probability of Efficacy Onset as Measured by at Least 20% Sustained Reduction From Baseline in the HAMD-17 Maier Subscale at Week 3
Time Frame: Week 3
|
Patients are considered to have met onset (visitwise binary outcome, yes/no) criteria at a particular visit if they had at least 20% reduction from baseline in the HAMD-17 Maier subscale at that visit and at all subsequent visits in the acute phase.
Maier subscale measures core symptoms of depression and scores range from 0 (normal) to 24 (severe).
The visitwise probability of patients meeting onset criteria was analyzed using a categorical, pseudo-likelihood-based repeated measures approach.
|
Week 3
|
Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Time Frame: baseline (Week 1), Week 13, Week 25
|
baseline (Week 1), Week 13, Week 25
|
|
Change From Baseline in Pulse Rate
Time Frame: baseline (Week 1), Week 13, Week 25
|
baseline (Week 1), Week 13, Week 25
|
|
Change From Baseline in Weight
Time Frame: baseline (Week 1), Week 13, Week 25
|
baseline (Week 1), Week 13, Week 25
|
|
Number of Participants With Abnormal Vital Signs and Weight at Any Time During the Study
Time Frame: Baseline (Week 1) through Week 25
|
A patient has a treatment-emergent elevated supine systolic blood pressure if the value is ≥140 with an increase ≥10 from baseline. A patient has a treatment-emergent elevated supine diastolic blood pressure if the value is ≥90 with an increase ≥10 from baseline. A patient has a treatment-emergent elevated supine pulse if the value is ≥100 with an increase ≥10 from baseline. A patient has abnormal weight change if the gain or loss is ≥7% compared to baseline. |
Baseline (Week 1) through Week 25
|
Number of Participants Experiencing Sustained Hypertension (SH) or Orthostatic Hypotension (OH)
Time Frame: baseline (Week 1) through Week 25
|
Sustained Hypertension is defined as supine systolic BP >= 140 (or diastolic BP >= 90) mm Hg and increase from baseline (highest value in baseline visit interval) >= 10 mm Hg for 3 or more consecutive visits in postbaseline visit interval.
Orthostatic Hypotension is defined as standing diastolic BP at least 10 mm Hg less than the supine diastolic BP or the standing systolic BP at least 20 mm Hg less than the supine systolic BP at any time in postbaseline visit interval and a patient does not meet this criterion at any visit in baseline interval.
|
baseline (Week 1) through Week 25
|
Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation
Time Frame: baseline (Week 1) through Week 25
|
Adverse Events and Serious Adverse Events leading to study discontinuation.
|
baseline (Week 1) through Week 25
|
Change From Baseline in Laboratory Values - Platelet Count
Time Frame: baseline (Week 1), Week 13, Week 25
|
Results are reported for laboratory analytes that exhibited statistically significantly different changes from baseline to endpoint between treatment groups.
Statistical significance was considered at the 0.05 level.
|
baseline (Week 1), Week 13, Week 25
|
Change From Baseline in Laboratory Values - Uric Acid
Time Frame: baseline (Week 1), Week 13, Week 25
|
Results are reported for laboratory analytes that exhibited statistically significantly different changes from baseline to endpoint between treatment groups.
Statistical significance was considered at the 0.05 level.
|
baseline (Week 1), Week 13, Week 25
|
Change From Baseline in Laboratory Values - Erythrocyte Count
Time Frame: baseline (Week 1), Week 25
|
Results are reported for laboratory analytes that exhibited statistically significantly different changes from baseline to endpoint between treatment groups.
Statistical significance was considered at the 0.05 level.
|
baseline (Week 1), Week 25
|
Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)
Time Frame: baseline (Week 1), Week 25
|
Results are reported for laboratory analytes that exhibited statistically significantly different changes from baseline to endpoint between treatment groups.
Statistical significance was considered at the 0.05 level.
|
baseline (Week 1), Week 25
|
Change From Baseline in Laboratory Values - Chloride and Fasting Glucose
Time Frame: baseline (Week 1), Week 25
|
Results are reported for laboratory analytes that exhibited statistically significantly different changes from baseline to endpoint between treatment groups.
Statistical significance was considered at the 0.05 level.
|
baseline (Week 1), Week 25
|
Number of Participants With Abnormal Laboratory Values - Low Leukocyte Count
Time Frame: baseline (Week 1) through Week 13
|
The number of participants with abnormal laboratory values at any time during the study period.
Results are reported for laboratory analytes that exhibited statistically significantly different proportions of participants who had abnormal values between treatment groups.
Statistical significance was considered at the 0.05 level.
The lower limit of normal for leukocyte count is 3.8 Billion/Liter.
Participants who had a value below that number were considered to have abnormally low leukocyte count.
|
baseline (Week 1) through Week 13
|
Change From Baseline in Electrocardiograms
Time Frame: baseline (Week 1), Week 25
|
The Electrocardiogram measures include the following time intervals: QT interval, QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF), QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB), PR interval and QRS interval.
|
baseline (Week 1), Week 25
|
Number of Participants With Successful Treatment Outcome
Time Frame: Baseline (Week 1) through Week 25
|
Successful treatment outcome defined as: Participant completed the study and being in remission (HAMD-17 Total score ≤7 and ≤10) at least for the last two visits (4 weeks)of the study.
The HAMD-17 is used to assess the severity of depression.
The total score ranges from 0 (not at all depressed) to 52 (severely depressed).
|
Baseline (Week 1) through Week 25
|
Change From Baseline on Cognitive Test Scores: Verbal Learning and Recall Test (VLRT), Symbol Digit Substitution Test (SDST), Trail Making Test (Part B), 2-Digit Cancellation Test (2DCT), and the Composite Cognitive Score Derived From the Above Scores
Time Frame: baseline (Week 1), Week 9, Week 25
|
The cognitive assessment battery is composed of four tests: Verbal Learning (score 0-15)and Delayed Recall(score 0-15) test, SDST(Score 0-133),2DCT(score 0-40),Trail Making(Part B)(score 0-180).They are designed to challenge the patient's abilities in the following areas: verbal learning and memory; attention to visually presented material; and working memory and executive function.
Composite Cognitive score(0-51)is derived from normalized individual test scores.
For Trail Making Test,lower number indicates better cognition.
For all other test scores,higher number indicates better cognition.
|
baseline (Week 1), Week 9, Week 25
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Harada E, Kato M, Fujikoshi S, Wohlreich MM, Berggren L, Tokuoka H. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials. Int J Clin Pract. 2015 Oct;69(10):1139-48. doi: 10.1111/ijcp.12658. Epub 2015 May 16.
- Nelson JC, Oakes TM, Liu P, Ahl J, Bangs ME, Raskin J, Perahia DG, Robinson MJ. Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trial. Prim Care Companion CNS Disord. 2013;15(1):PCC.12m01419. doi: 10.4088/PCC.12m01419. Epub 2012 Jan 3.
- Oakes TM, Katona C, Liu P, Robinson M, Raskin J, Greist JH. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies. Int Clin Psychopharmacol. 2013 Jan;28(1):1-11. doi: 10.1097/YIC.0b013e32835b09cd.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Mood Disorders
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
- 10815 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- F1J-US-HMFA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on duloxetine hydrochloride
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingMajor Depressive Disorder (MDD)China
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Completed
-
Eli Lilly and CompanyShionogiCompleted
-
Boehringer IngelheimCompletedDiabetic Neuropathies | Depressive Disorder, MajorGermany
-
Tasly Pharmaceutical Group Co., LtdRecruiting
-
Eli Lilly and CompanyCompletedDepressive DisorderUnited States
-
Eli Lilly and CompanyCompletedDiabetic Neuropathy, PainfulUnited States, Puerto Rico
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States
-
University of PittsburghEli Lilly and Company; National Institutes of Health (NIH)CompletedBack Pain | Major Depressive Disorder | AgedUnited States